The manufacturers suggest that
imatinib may inhibit the
metabolism of
warfarin. This suggestion seems to be based on an observation in one patient, and on
in vitro studies that show that
imatinib can inhibit CYP2C9, which is involved in the
metabolism of
warfarin. There seems to be no other evidence that a clinically relevant interaction is likely to occur.
The manufacturers say that patients needing anticoagulation should be given low- molecular-weight or standard heparin.